Diseases that may benefit from manipulating the Th17 pathway
Open Access
- 12 March 2009
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 39 (3) , 667-669
Abstract
The discovery of IL‐17 and of the Th17 pathway has been a step in the classification of human diseases. Th17 targeting appears rather straightforward in diseases associated with inflammation and matrix destruction, such as rheumatoid arthritis, psoriasis, and Crohn's disease. In other conditions where IL‐17 is expressed and Th17 activated, it is unclear whether this is a primary or secondary event, making the use of Th17 inhibitors less obvious.Keywords
Funding Information
- Hospices Civils de Lyon and the Région Rhône-Alpes
This publication has 40 references indexed in Scilit:
- Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansionBlood, 2008
- Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cellsJournal of Experimental Medicine, 2008
- Th17 cells in human diseaseImmunological Reviews, 2008
- Regulation of inflammatory responses by IL-17FJournal of Experimental Medicine, 2008
- IL-22 mediates mucosal host defense against Gram-negative bacterial pneumoniaNature Medicine, 2008
- Th17: the third member of the effector T cell trilogyCurrent Opinion in Immunology, 2007
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJournal of Experimental Medicine, 2007
- IL-23 mediates inflammatory responses to mucoidPseudomonas aeruginosalung infection in miceAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003